Table 2. Association of H2RA Use at Baseline and HF.

	Adjusted Risk of HF in H2RA Users Relative to Nonusers (N = 6,378)
	Hazard Ratio	95% CI	p Value
Unadjusted	0.52	0.23 to 1.18	0.12
Limited adjustment*	0.40	0.18 to 0.90	0.03
Full adjustment†	0.38	0.17 to 0.86	0.02
Full adjustment† + comedication use‡	0.35	0.16 to 0.80	0.01
Full adjustment† + NT-proBNP & troponin T (n = 5,285)	0.18	0.05 to 0.62	0.007
Restricted to H2RA users and PPI users§ (n = 698)	0.42	0.15 to 1.16	0.09
Restricted to PS matched participants§ (n = 593)	0.31	0.11 to 0.86	0.03

^*Limited adjustment accounts for age, sex, race/ethnicity, height, weight, and study site.

^†Full adjustment accounts for the limited model and education, cigarette smoking, pack-years, hypertension, systolic blood pressure, diabetes, cholesterol, glucose, and daily exercise.

^‡Comedication use included NSAIDs (aspirin, Cox-2 inhibitors, and other nonsteroidal inflammatory medications), steroids, beta-blockers (± diuretics), ACE inhibitors (± diuretics), ARBs (± diuretics), any diuretic alone (including potassium-sparking diuretics), leukotriene antagonists, and digoxin.

^§Participants in the restricted cohorts were considered in models with full adjustment.

CI = confidence interval; PPI = proton pump inhibitor; PS = propensity score; other abbreviations as in Table 1.